Potential cost-effectiveness and benefit-cost ratios of adult Pneumococcal vaccination in Germany

Health Economics Review

Volumn 2, Issue 1, 2012, Pages 1-13

  Kuhlmann, Alexander ^a   Theidel, Ulrike ^b   Pletz, Mathias W ^c   von der Schulenburg, J Matthias Graf ^a  

^a Institute for Risk and Insurance   (Germany)

^b Herescon GmbH   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Adult; Benefit cost I; Cost; Effectiveness; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULTHOOD; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DRUG DOSAGE FORM COMPARISON; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; INFECTION PREVENTION; MORTALITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; STREPTOCOCCUS PNEUMONIA; VACCINATION;

EID: 84971238029     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-2-4     Document Type: Article

References (56)

1. Rueckinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A: Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27:4136-4141.
2. Conaty S, Watson L, Dinnes J, Waugh N: The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004, 22:3214-3224.
3. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M: Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001, 19:4780-4790.
4. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN: Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154:2666-2677.
5. Go ES, Ballas ZK: Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996, 98:205-215.
6. Huss A, Scott P, Stuck AE, Trotter C, Egger M: Efficacy of pneumococcal vaccination in adults: a meta-analysis. Canadian Medical Association Journal 2009, 180:48-58.
7. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K: Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999, 45:2381-2393.
8. Mangtani P, Cutts F, Hall AJ: Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003, 3:71-78.
9. Moberley S, Holden J, Tatham DP, Andrews RM: Vaccines for preventing pneumococcal infection in adults (Review). Cochrane Database Syst Rev 2008,:CD000422. doi:10.1002/14651858.CD000422.pub2.
10. Morre RA, Wiffen PJ, Lipsky BA: Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Publ Health 2000, 1:1-10.
11. Puig-Barbera J, Belenguer VA, Goterris PM, Brines Benlliure MJ: Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis. Aten Primaria 2002, 30:269-281.
12. Watson L, Wilson BJ, Waugh N: Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002, 20:2166-2173.
13. Paradiso PR, Gruber WC: The Potential of Pneumococcal Conjugate Vaccine in Adults. [Abstract] Presented at the Sixth International Symposium on Pneumococci and Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008. 2011.
14. Statistisches Bundesamt (Hrsg.): Bevölkerung nach Altersgruppen, Familienstand und Religionszugehörigkeit. http://www.destatis.de.
15. Robert Koch-Institut: Empfehlungen der Ständigen Impfkomission (STIKO). http://www.rki.de/cln_178/nn_2030884/DE/Content/Infekt/EpidBull/Archiv/2011/30__11,templateId=raw,property=publicationFile.pdf/30_11.pdf.
16. Adam D, Busse A: Pneumokokkenkonjugatimpfstoffe: Expertenkonsensuspapier zum aktuellen Stand der Dinge. Monatsschrift Kinderheilkunde 2009, 157:1252-1256.
17. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, Gruber WC, Lockhart S, Burkhardt O, Welte T, Lode HM: Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46:1015-1023.
18. Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, Schmoele-Thoma B: A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Vaccine 2011, 29:5195-5202.
19. Koch-Institut R: Mitteilung der Ständigen Impfkommission am Robert Koch-Institut Pneumokokken-Polysaccharid-Impfung - Anpassung der Empfehlung und Begründung. Epidemiologisches Bulletin 2009, 32:337-338.
20. Statistisches Bundesamt: Sterbetafel 2007/9. http://www.destatis.de.
21. Fleming DM, Elliot AJ: Estimating the risk population in relation to influenza vaccination policy. Vaccine 2006, 24:4378-4385.
22. Statistisches Bundesamt (Hrsg.): Diagnosedaten der Krankenhäuser nach Behandlungsort ab 2000 (Fälle/Sterbefälle, Pflegetage, durchschnittliche Verweildauer. Gliederungsmerkmale: Jahre, Behandlungsort, Alter, Geschlecht, Verweildauer, ICD10. http://www.gbe-bund.de.
23. Institut für Qualität und Patientensicherheit: BQS-Qualitätsreport. 2008. http://www.bqs-qualitaetsreport.de/2008/ergebnisse/down.
24. IMS Health Deutschland: Verschreibungsindex für Pharmazeutika (VIP). 2009. Unpublished Work.
25. CapNetz: CAP Moratlitätsdaten. 2009. Unpublished Work.
26. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
27. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21:810-815.
28. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006, 25:779-781.
29. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D'Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, Takei Y, Gabazza EC: Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. British Medical Journal 2010, 340:c1004.
30. Reinert RR, Haupts S, van der Linden M, Heeg C, Cil MY, Al-Lahham A, Fedson DS: Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect 2005, 11:985-991.
31. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR: Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
32. Metlay JP, Fishman NO, Joffe M, Edelstein PH: Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006, 24:468-475.
33. Moore M, Pilishvili T, Farley MM: Trends in invasive pneumococcal pneumonia, selected U.S. Sites 1998-2006 [Abstract] n.A. 2008.
34. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB: Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25:494-501.
35. Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R, Brown M, Gilbert L, Hogg G, Murphy D: Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008, 32:18-30.
36. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
37. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
38. Claes C, Reinert RR, von der Schulenburg JM: Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 2009, 10:25-38.
39. World Health Organisation: Initiative for Vaccine Research (IVR). www.who.int.
40. Institut für das Entgeltsystem im Krankenhaus: DRG Browser 2008_2010. 2010. http://www.g-drg.de.
41. Imran MN, Leng PH, Yang S, Kurup A, Eng P: Early predictors of mortality in pneumococcal bacteraemia. Ann Acad Med Singapore 2005, 34:426-431.
42. Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, Jorup C, Julander I, Marrie TJ, Mufson MA, Riquelme R, Thalme A, Torres A, Woodhead MA: Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000, 182:840-847.
43. Kassenärztliche Bundesvereinigung: Einheitlicher Bewertungsmaßstab (EBM). http://www.kbv.de.
44. Lauertaxe: Arzneimittelpreise. https://www.lauer-fischer.de/LF/Seiten/Verwaltung/Kundencenter.aspx.
45. von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C: German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. Value Health 2008, 11:539-544.
46. Statistisches Bundesamt: Arbeitsunfähigkeit bei AOK-Pflichtmitgliedern ohne Rentner (Arbeitsunfähigkeitsfälle, Arbeitsunfähigkeitstage, Tage je Fall). Gliederungsmerkmale: Jahre, Deutschland, Geschlecht, ICD-10. http://www.destatis.de.
47. Statistisches Bundesamt (Hrsg.): Bevölkerung, Erwerbstätige, Erwerbslose, Erwerbspersonen, Nichterwerbspersonen: Deutschland, Jahre, Altersgruppen. http://www.destatis.de.
48. Schnoor M, Klante T, Beckmann M, Robra BP, Welte T, Raspe H, Schafer T: Risk factors for community-acquired pneumonia in German adults: the impact of children in the household. Epidemiol Infect 2007, 135:1389-1397.
49. Jackson L, Rice K, Lauksens K, Greenberg R, Jones T, Jayawardene D, Love J, Scott D, Emini E, Gruber W, Schoele-Thoma B: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. [Abstract] Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th International Congress of Chemotherapy (ICC); Milan, Italy May 7-May 10, 2011. [oral presentation]
50. Jackson L, Gurtman A, van Cleeff M, Jansen K, Jayawardene D, Devlin C, Scortt D, Emini E, Gruber W, Schmoele-Thoma B: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in pneumococcal naïve adults 50 through 64 years of age. [Abstract]. Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/ 27th International Congress of Chemotherapy (ICC); Milan, Italy May 7-May 10, 2011. [oral presentation]
51. van der Linden M, Imoehl M: Invasive Pneumokokkenerkrankungen bei Erwachsenen in Deutschland: Bestandsaufnahme vier Jahre nach Einführung der Pneumokokken-Konjugatimpfung bei Kindern [Abstract] Presented at the 2nd National Vaccination Conference in Stuttgart vom February 8-Februar 9, 2011.
52. Ardanuy C, Tubau F, Pallares R, Catalayud L, Dominguez MA, Rolo D, Grau I, Martín R, Linares J: Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2011, 48:57-64.
53. van der Linden M: Replacement of serotypes in Germany. Personal Communication.
54. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M: Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009, 27:4891-4904.
55. Weycker D, Sato R, Strutton D, Edelsberg J, Jackson LA: Public Health and Economic Impact of PCV13 in US Adults Aged > = 50. Infectious Diseases Society of America 2010, 462.
56. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ: Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged>or =65 years in the Netherlands. Clin Ther 2010, 32:1517-1532.